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Saphenous Vein Graft Lesions
Wiisanen et al. (1) performed a meta-analysis of 23 studies
comparing drug-eluting stents (DES) with bare-metal stents for
saphenous vein graft lesions, and they demonstrated the supe-
riority of DES in reducing death, myocardial infarction, and
target vessel revascularization. Eleven meta-analyses have been
published thus far on the same subject in a little over 1 year,
whereas the number of primary studies has remained more or
less the same (29 studies involving 7,994 patients) (2). All these
meta-analyses have yielded similar results showing that DES
reduced the risk of major adverse cardiac events predominantly
driven by a lower target lesion revascularization. So how does the
meta-analysis by Wiisanen et al. (1) add new information? Specifi-
cally, the investigators have included “duplicate” data. They have
included 4 randomized controlled trials. In reality, there are only 2
randomized comparisons of DES with bare-metal stents for saphe-
nous vein graft lesions—the SOS (Stenting of Saphenous VeinGrafts)
and RRISC (Reduction of Restenosis In Saphenous Vein Grafts With
Cypher Sirolimus-Eluting Stent) trials. Wiisanen et al. (1) have included
both short- and long-term outcome studies for the RRISC trial (same
patient population counted twice). The third included randomized
controlled trial is a subgroup analysis from the BASKET (Basal Stent
Cost-Effectiveness Trial) and not a randomized comparison. Analyzing
the data on the same patients more than once may lead to significantly
biased estimates of efficacy and safety (3).
We identified 11 meta-analyses (and perhaps a few more in
the pipeline) with more than 8 published in 6 months by
different investigators (Online Table 1). Is there any “novelty”
in terms of incremental scientific value of these publications or
are they just redundant. Which of these 11 papers should be
cited and what would be the criteria? Is the criterion the number
of studies and included patients? Publication date? Quality of
the meta-analysis? Or the reputation of the journal? These
issues and their potential negative impact have been raised by a few
reports (3–5). It might be a consequence of multiple cardiology
journals with rapid review turnaround times, online publication ahead
of print, and so forth, so we believe reorganizing the process in which
meta-analyses are conceived, designed, executed, and reviewed could
help address some of these issues (4,5). Authors should be required to
submit their proposals in a central registry like clinicaltrials.gov or
others recently proposed (5). Submitted meta-analysis should be
rigorously evaluated for accuracy of data and careful scrutiny to avoid
issues such as overlapping/redundant data. Further evaluation of
statistical methods by a dedicated statistician (as mandated by a few
journals) would also be helpful. Journals should lay out comprehensive
guidelines for meta-analysis in their “Instructions for Authors” sec-
tion.
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APPENDIX
To see a table with the details of the 11 meta-analyses referred to in the text,
please see the online version of this paper.
Drug-Eluting Stents for
Saphenous Vein Graft Interventions
I read with interest the meta-analysis by Wiisanen et al. (1)
regarding stents in saphenous vein graft interventions. I was
surprised to see that the RRISC (Reduction of Restenosis In
Saphenous vein grafts with Cypher sirolimus-eluting stent) trial
is counted twice in the analysis of the randomized controlled
trials. This study included 38 patients in the drug eluting stents
(DES) and 37 in the bare-metal stents categories. The initial
publication reports the 6-month outcome (2), whereas the
second publication reports long-term outcome of the same
patients (3). Counting these patients twice is obviously wrong.
Unfortunately, this error leads to wrong conclusions such as, for
example, the conclusion from the correct analysis of mortality in
